Analysis Of P-RB Expression And CPT-11 Efficacy In Recurrent Epithelial Ovarian Cancer

Objective: By detecting the phosphorylation of RB protein(phosho-RB)expression in recurrent epithelial ovarian carcinoma and analyzing its correlation with irinotecan hydrochloride(CPT-11)based chemotherapy after recurrence,our objective was to provide a theoretical basis for individualized treatment in patients with ovarian cancer.Methods: We Chose 27 recurrent epithelial ovarian cancer patients from the Second Affiliated Hospital of Dalian Medical University whose first-line chemotherapy failure and underwent second line and above CPT-11 chemotherapy during January 2002 to September 2016,then collected patients' complete medical records and surgical tumor specimens.Meanwhile,normal ovarian tissues paraffin specimens of 27 cases with ovarian cyst resection during the same period were collected.We detected the expression of phosphorylated RB protein in tissues by immunohistochemistry and then we used statistical methods for analysis of the relationship between phosphorylated RB protein expression and clinicopathological features of patients(type of first-line chemotherapy,platinum sensitive or not,FIGO stage,pathological type,histological grade,presence of ascites and lymph node metastasis)as well as CPT-11 efficacy after recurrence.Results: 1.The positive rate of phosho-RB in patients with epithelial ovarian cancer(62.96%)was significantly higher than that in normal ovarian tissues(22.22%),the difference between these two groups was statistically significant(P<0.05).The expression of phosho-RB had no obvious relationship with patient's lymph node metastasis,the possibility of platinum sensitive,FIGO staging,histological grade,the initial symptom of ascites,pathological type,age,whether neoadjuvant chemotherapy and type of first-line chemotherapy(P > 0.05).2.The positive expression of phosho-RB protein in epithelial ovarian tumors was significantly associated with irinotecan-based chemotherapy disease control rates(CR+PR+SD)(P= 0.000).3.Univariate analysis showed that for PFS,phosho-RB expression,FIGO staging,lymph node metastasis,initial symptoms with or without ascites for factors affecting PFS after irinotecan chemotherapy in recurrent epithelial ovarian cancer patients(P <0.05).There was no significant correlation among the age of patients,the degree of differentiation of tumor tissue,the possibility of platinum sensitive,type of first-line chemotherapy,whether neoadjuvant chemotherapy and different pathological types for PFS in recurrent epithelial ovarian cancer patients(P >0.05).Further multivariate analysis showed that phosho-RB expression was an independent prognostic factor for PFS in the recurrent epithelial ovarian cancer patients who accepted irinotecan-based chemotherapy(P <0.05).4.Univariate analysis showed that for survival after accepting CPT-11 therapy,there was no significant correlation among the phosho-RB expression,FIGO staging,lymph node metastasis,the age of the patients,histological grade,the symptom of ascites,the possibility of platinum sensitive,whether neoadjuvant chemotherapy,the pathological types and type of first-line chemotherapy for recurrent epithelial ovarian cancer(P > 0.05).Conclusion: 1.The positive rate of phosho-RB in epithelial ovarian cancer was significantly higher than that in normal ovarian tissues,which suggested that it may be involved in the occurrence of epithelial ovarian cancer.2.For patients with recurrent epithelial ovarian cancer,p-RB expression was significantly correlated with CPT-11 disease control rates and PFS,which could be a predictor for recurrent patients who accept CPT-11 therapy after first-line chemotherapy failure.